Cargando…
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies, including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors, have obtained unprecedented benefit in multiple malignancies. However, t...
Autores principales: | Tang, Liansha, Wang, Jialing, Lin, Nan, Zhou, Yuwen, He, Wenbo, Liu, Jiyan, Ma, Xuelei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724248/ https://www.ncbi.nlm.nih.gov/pubmed/34992611 http://dx.doi.org/10.3389/fimmu.2021.800879 |
Ejemplares similares
-
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
por: Zhang, Qin, et al.
Publicado: (2021) -
Neurological Adverse Events Induced by Immune Checkpoint Inhibitors
in Non-Small Cell Lung Cancer: Current Perspectives and New
Development
por: Cheng, Ke, et al.
Publicado: (2021) -
Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021) -
Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
por: Zhou, Guanzhou, et al.
Publicado: (2022) -
The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application
por: Han, Xu, et al.
Publicado: (2022)